A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is testing a targeted anti-cancer medication called ifinatamab deruxtecan (I-DXd) to see how safe and effective it is for various types of solid tumors that have returned or spread. Researchers hope this treatment will help patients who need new options when standard therapies have stopped working.
You may be able to join if you are 18 or older, able to carry out light daily activities, have measurable tumors that worsened after standard treatment, and can provide a tumor tissue sample. There are specific rules regarding past treatments and active brain metastases.
Participants will receive the study medication, ifinatamab deruxtecan, and have their health and tumor size monitored closely through scans like CTs or MRIs. Your care team will watch you carefully for any side effects and see how your body responds to the treatment.
This study is currently recruiting patients and has locations in places such as Los Angeles and Whittier, California, in the United States.
- 1Testing a targeted anti-cancer medication called ifinatamab deruxtecan.
- 2Open to adults with various types of advanced solid tumors that have progressed.
- 3Currently actively recruiting participants at locations in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.